Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...

Since the FDA said shortages of Wegovy and Zepbound are over, compounding pharmacies are supposed to stop making copies of the drugs. But some of those business are trying to find ways to continue.

Orforglipron (pronounced or-for-GLIP-ron) might be a mouthful to say, but Indianapolis-based Eli Lilly and Co. sees this ...

Talk to your healthcare provider about how you can take part in this registry, or you may contact Lilly at 1-800-LillyRx (1-800-545-5979). Zepbound ... between our sales teams and authors ...

The supply of GLP-1 drugs for weight loss and diabetes treatment was expected to tighten this week with a federal deadline to halt the sale ... Zepbound and Mounjaro from competitor Eli Lilly.

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to halt the sale and production of off-brand products that many patients in ...

Novo Nordisk has been ceding market share to Eli Lilly, even though Zepbound's dollar sales still trail Wegovy ... the body and doesn't require dietary restrictions like oral semaglutide does ...